The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization

Pain

Volumn 122, Issue 3, 2006, Pages 315-325

  Gazerani, Parisa ^a   Staahl, Camilla ^a,b   Drewes, Asbjøn M ^a,b   Arendt Nielsen, Lars ^a  

^a AALBORG UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Botulinum Toxin type A; Capsaicin; Experimental pain; Migraine; Sensitization; Trigeminal

Indexed keywords

BOTULINUM TOXIN A; CAPSAICIN; SODIUM CHLORIDE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; BLOOD FLOW; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FACE; FOREHEAD; HUMAN; HYPERALGESIA; MALE; MUSCLE WEAKNESS; NECK PAIN; NOCICEPTION; NOCICEPTIVE RECEPTOR; PAIN; PAIN THRESHOLD; PRESSURE; PRIORITY JOURNAL; SENSITIZATION; SKIN RECEPTOR; SKIN TEMPERATURE; TRIGEMINAL NERVE; VASOMOTOR REFLEX; CHEMICALLY INDUCED DISORDER; INTRADERMAL DRUG ADMINISTRATION; PAIN ASSESSMENT; PATHOLOGY; PATHOPHYSIOLOGY; URTICARIA; VASCULARIZATION;

ADULT; BOTULINUM TOXIN TYPE A; CAPSAICIN; FACE; FOREHEAD; HUMANS; HYPERALGESIA; INJECTIONS, INTRADERMAL; MALE; PAIN; PAIN MEASUREMENT; PAIN THRESHOLD; PRESSURE; REGIONAL BLOOD FLOW; SKIN TEMPERATURE; TRIGEMINAL NERVE; URTICARIA;

EID: 33745000127     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2006.04.014     Document Type: Article

References (67)

1. Aoki K.R. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 43 Suppl. 1 (2003) S9-S15
2. Aoki K.R. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 26 5 (2005) 785-793
3. Arezzo J.C. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain 18 6 Suppl. (2002) S125-S132
4. Argoff C.E. A focused review on the use of botulinum toxins for neuropathic pain. Clin J Pain 18 6 Suppl. (2002) S177-S181
5. Ashkenazi A., and Silberstein S.D. Botulinum toxin and other new approaches to migraine therapy. Annu Rev Med 55 (2004) 505-518
6. Ashkenazi A., and Silberstein S.D. The evolving management of migraine. Curr Opin Neurol 16 3 (2003) 341-345
7. Bach-Rojecky L., and Lackovic Z. Antinociceptive effect of Botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat Med J 46 2 (2005) 201-208
8. Bach-Rojecky L., Relja M., and Lackovic Z. Botulinum toxine type A in experimental neuropathic pain. J Neural Transm 112 (2005) 215-219
9. Binder W.J., Blitzer A., and Brin M.F. Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg 24 11 (1998) 1198-1205
10. Blersch W., Schulte-Mattler W.J., Przywara S., May A., Bigalke H., and Wohlfarth K. Botulinum toxin A and the cutaneous nociception in humans: a prospective, double-blind, placebo-controlled, randomized study. J Neurol Sci 205 1 (2002) 59-63
11. Blumenfeld A.M., Binder W., Silberstein S.D., and Blitzer A. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 43 8 (2003) 884-891
12. Bovim G. Cervicogenic headache, migraine, and tension-type headache. Pressure-pain threshold measurements. Pain 51 2 (1992) 169-173
13. Brin M.F., Fahn S., Moskowitz C., Friedman A., Shale H.M., Greene P.E., et al. Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm. Mov Disord 2 4 (1987) 237-254
14. Brin M.F., Swope D.M., O'Brain C., Aboasi S., and Pogoda J.M. Botox for migraine: double-blind, placebo controlled region-specific evaluation. Cephalalgia 20 (2000) 421-422
15. Burstein R., Cutrer M.F., and Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123 Pt. 8 (2000) 1703-1709
16. Burstein R., Yarnitsky D., Goor-Aryeh I., Ransil B.J., and Bajwa Z.H. An association between migraine and cutaneous allodynia. Ann Neurol 47 5 (2000) 614-624
17. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 89 2-3 (2001) 107-110
18. Burstein R., Collins B., and Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55 1 (2004) 19-26
19. Cheshire W.P., Abashian S.W., and Mann J.D. Botulinum toxin in the treatment of myofascial pain syndrome. Pain 59 1 (1994) 65-69
20. Criscuolo C.M. Interventional approaches to the management of myofacial pain syndrome. Curr Pain Headache Rep 5 5 (2001) 407-411
21. Cruccu G., Anand P., Attal N., Garcia-Larrea L., Haanpaa M., Jorum E., et al. EFNS guidelines on neuropathic pain assessment. Eur J Neurol 11 3 (2004) 153-162
22. Cui M., Khanijou S., Rubino J., and Aoki K.R. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107 1-2 (2004) 125-133
23. Cui M., Li S., You S., Khanijou S., and Aoki K.R. Mechanisms of the antinociceptive effect of subcutaneous Botox inhibition of peripheral and central nociceptive processing (abstract). Naunyn Schmiedebergs Arch Pharmacol 365 Suppl. 2 (2002) R17
24. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 43 Suppl. 1 (2003) S16-S24
25. Difazio M., and Jabbari B. A focused review of the use of botulinum toxins for low back pain. Clin J Pain 18 6 Suppl. (2002) S155-S162
26. Duggan M.J., Quinn C.P., Chaddock J.A., Purkiss J.R., Alexander F.C., Doward S., et al. Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 277 38 (2002) 34846-34852
27. Durham P.L., Cady R., and Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implication for migraine therapy. Headache 44 1 (2004) 35-42
28. Durham P.L., and Russo A.F. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 19 9 (1999) 3423-3429
29. Essex T.J.H., and Byrne P.O. A laser Doppler scanner for imaging blood flow in skin. J Biomed Eng 13 (1991) 189-193
30. Evers S., Rahmann A., Vollmer-Haase J., and Husstedt I.W. Treatment of headache with botulinum toxin A - a review according to evidence-based medicine criteria. Cephalalgia 22 9 (2002) 699-710
31. Evers S. Is there a role for botulinum toxin in the treatment of migraine?. Curr Pain Headache Rep 7 3 (2003) 229-234
32. Fischer A.A. Pressure algometry over normal muscles. Standard values, validity and reproducibility of pressure threshold. Pain 30 1 (1987) 115-126
33. Fischer A.A. Reliability of the pressure algometer as a measure of myofascial trigger point sensitivity. Pain 28 3 (1987) 411-414
34. Forster C., Greiner T., Nischik M., Schmelz M., and Handwerker H.O. Neurogenic flare responses are heterogeneous in superficial and deep layers of human skin. Neurosci Lett 185 (1995) 33-36
35. Francis J.E., Rogli R., Love T.J., and Robinson C.P. Thermography as a means of blood perfusion measurement. J Biomech Eng 101 (1979) 246-249
36. Goadsby P.J., Lipton R.B., and Ferrari M.D. Migraine-current understanding and treatment. N Engl J Med 346 4 (2002) 257-270
37. Gobel H., Heinze A., Heinze-Kuhn K., and Austermann K. Botulinum toxin A in the treatment of headache syndromes and pericranial pain syndromes. Pain 91 3 (2001) 195-199
38. Guyer B.M. Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 3 6 (1999) 427-431
39. Holzer P. Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43 2 (1991) 143-201
40. Ishikawa H., Mitsui Y., Yoshitomi T., Mashimo K., Aoki S., Mukuno K., et al. Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 44 2 (2000) 106-109
41. Jabbari B., Maher N., and Difazio M.P. Botulinum toxin a improved burning pain and allodynia in two patients with spinal cord pathology. Pain Med 4 2 (2003) 206-210
42. Jakubowski M., Levy D., Goor-Aryeh I., Collins B., Bajwa Z., and Burstein R. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 45 7 (2005) 850-861
43. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 75 7 (2004) 951-957
44. Kamanli A., Kaya A., Ardicoglu O., Ozgocmen S., Zengin F.O., and Bayik Y. Comparison of lidocaine injection, botulinum toxin injection, and dry needling to trigger points in myofascial pain syndrome. Rheumatol Int 25 8 (2004) 604-611
45. Kellogg Jr. D.L., Pergola P.E., Piest K.L., Kosiba W.A., Crandall C.G., Grossmann M., et al. Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. Circ Res 77 6 (1995) 1222-1228
46. Kinkelin I., Hund M., Naumann M., and Hamm H. Effective treatment of frontal hyperhidrosis with Botulinum toxin A. Br J Dermatol 143 (2000) 824-827
47. Koltzenburg M., Lundberg L.E., and Torebjork H.E. Dynamic and static components of mechanical hyperalgesia in human hairy skin. Pain 51 2 (1992) 207-219
48. Kramer H.H., Angerer C., Erbguth F., Schmelz M., and Birklein F. Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skin. J Neurol 250 2 (2003) 188-193
49. LaMotte R.H., Shain C.N., Simone D.A., and Tsai E.F. Neurogenic hyperalgesia psychophysical studies of underlying mechanisms. J Neurophysiol 66 1 (1991) 190-211
50. LaMotte R.H., Lundberg L.E., and Torebjork H.E. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol 448 (1992) 749-764
51. Magerl W., Szolcsanyi J., Westerman R.A., and Handwerker H.O. Laser Doppler measurements of skin vasodilation elicited by percutaneous electrical stimulation of nociceptors in humans. Neurosci Lett 82 (1987) 349-354
52. Malick A., and Burstein R. Peripheral and central sensitization during migraine. Funct Neurol 15 Suppl. 3 (2000) 28-35
53. May A., Kaube H., Buchel C., Eichten C., Rijntjes M., Juptner M., et al. Experimental cranial pain elicited by capsaicin: a PET study. Pain 74 1 (1998) 61-66
54. Morris J.L., Jobling P., and Gibbins I.L. Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 281 5 (2001) H2124-H2132
55. Ondo W.G., Vuong K.D., and Derman H.S. Botulinum toxin A for chronic daily headache: a randomized, placebo-controlled, parallel design study. Cephalalgia 24 1 (2004) 60-65
56. Purkiss J., Welch M., Doward S., and Foster K. Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochem Pharmacol 59 11 (2000) 1403-1406
57. Quinn A.G., McLelland J., Essex T., and Farr P.M. Measurement of cutaneous inflammatory reactions using a scanning laser Doppler velocimeter. Br J Dermatol 125 (1991) 30-37
58. Serra J., Campero M., and Ochoa J. Flare and hyperalgesia after intradermal capsaicin injection in human skin. J Neurophysiol 80 (1998) 2801-2810
59. Silberstein S.D., and Goadsby P.J. Migraine: preventive treatment. Cephalalgia 22 7 (2002) 491-512
60. Silberstein S.D. Review of botulinum toxin type A and its clinical applications in migraine headache. Expert Opin Pharmacother 2 10 (2001) 1649-1654
61. Silberstein S.D., Stark S.R., Lucas S.M., Christie S.N., Degryse R.E., Turkel C.C., and BoNTA-039 Study Group. Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc 80 9 (2005) 1126-1137
62. Simpson L.L. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev 33 3 (1981) 155-188
63. Sycha T., Samal D., Chizh B., Lehr S., Gustorff B., Schnider P., et al. A lack of antinociceptive or anti-inflammatory effect of botulinum toxin A in an inflammatory human pain model. Anesth Analg 102 2 (2006) 509-516
64. Tsui J.K., Eisen A., Stoessl A.J., Calne S., and Calne D.B. Double-blind study of botulinum toxin in spasmodic torticollis. Lancet 2 8501 (1986) 245-247
65. Tugnoli V., Marchese Ragona R., Eleopra R., Quatrale R., Capone J.G., Pastore A., et al. The role of gustatory flushing in Frey's syndrome and its treatment with botulinum toxin type A. Clin Auton Res 12 3 (2002) 174-178
66. Voller B., Sycha T., Gustorff B., Schmetterer L., Lehr S., Eichler H.G., et al. A randomized, double-blind, placebo controlled study on analgesic effects of botulinum toxin A. Neurology 61 7 (2003) 940-944
67. Welch M.J., Purkiss J.R., and Foster K.A. Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon 38 2 (2000) 245-258